

May 25, 2021

Dear Dean Health Plan Provider:

Thank you for your continued dedication and commitment to providing high-quality care to our members during this public health emergency.

This notification contains information regarding:

- Updates to COVID-19 monoclonal antibody therapy coverage.
- U.S. Food and Drug Administration (FDA) emergency use authorization for the Pfizer-BioNTech COVID-19 vaccine for children 12 to 15 years old.
- Updated fee schedules for COVID-19 vaccine administration.

Information in this notification applies to the following Dean Health Plan products: Commercial (fully insured, including ACA), Dean Administrative Services Only (ASO), SSM Health Employee Health Plan ASO in Wisconsin, Medicare Advantage, and Medicaid.

Monoclonal Antibody Therapy Updates

Eli Lilly and Company's Bamlanivimab, Administered Alone

On April 16, 2021, the FDA [revoked emergency use authorization \(EUA\) for bamlanivimab](#) (HCPCS codes Q0239 and M0239), when administered alone. In alignment with the Centers for Medicare & Medicaid Services (CMS), the Health Plan will cover and reimburse bamlanivimab when administered alone and consistent with the terms of the EUA from November 10, 2020 through April 16, 2021.

Eli Lilly and Company's Bamlanivimab and Etesevimab, Administered Together

The EUA for the following Eli Lilly and Company's bamlanivimab and etesevimab, administered together, which became effective on February 9, 2021, remains in place:

- M0245 - Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring.

Effective for dates of service on and after May 6, 2021, the reimbursement rate for the administration of M0245 is increased.

Regeneron's Antibodies Casirivimab and Imdevimab

While EUA was issued on November 21, 2020, the following Regeneron's Antibodies Casirivimab and Imdevimab administration code became effective on May 6, 2021:

- M0244 - intravenous infusion, casirivimab and imdevimab includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency.

Effective for dates of service on and after May 6, 2021, the reimbursement rate for Regeneron's Antibodies Casirivimab and Imdevimab intravenous injection and post administration monitoring, procedure code M0243, is increased.

Claims and More Information

As a reminder, because the federal government furnishes monoclonal antibody therapies product, claims for the **product** itself should not be sent to the Health Plan. Claims for the **administration** should be sent to the Health Plan, except for Medicare Advantage claims.

Please refer to [Centers for Medicare and Medicaid Services \(CMS\) Monoclonal Antibody COVID-19 Infusion](#) for COVID-19 monoclonal antibody therapies details, including EUA, medical documentation, coding, billing, and payment.

COVID-19 Vaccines for Children Ages 12 to 15

On May 11, 2021, the FDA issued EUA for the administration of the Pfizer-BioNTech COVID-19 vaccine to children 12 to 15 years old. Please refer to our [November 24, 2020, COVID-19 Communication](#) for more Pfizer-BioNTech COVID-19 vaccine information.

Updated Fee Schedules

Dean Health Plan has updated fee schedules to reflect increased reimbursement rates for COVID-19 vaccine administration (CPT codes 0001A, 0002A, 0011A, 0012A, 0031A), on and after March 15, 2021.


Additional Health Plan Information

For additional health plan information and previous provider communications, refer to our [COVID-19 provider information web page](#) link located at the top of all [deancare.com](#) web pages. Providers are encouraged to check our website regularly for new and updated information.

Please contact your assigned Provider Network Consultant with any questions.

Thank you again for your continued care of our members.

Sincerely,



Loretta A. Lorenzen
Vice President- Network Management & Contracting